Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the...
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers.
Target Price
The average target price of RAPP is 49 and suggests 86% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell